Anti-XLF抗体;Anti-XLF Antibody—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P07705(XBP1 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using P07705(XBP1 Antibody) at dilution 1/70. (Original magnification: ×200)    

  
  

Anti-XLF antibody is a research tool used to detect XLF (XRCC4-like factor), also known as Cernunnos, a critical protein involved in DNA double-strand break (DSB) repair. XLF plays a key role in the non-homologous end joining (NHEJ) pathway, a major mechanism for repairing DSBs in mammalian cells. It interacts with XRCC4 and DNA Ligase IV (Lig4) to stabilize the repair complex, facilitating DNA ligation. XLF deficiency is linked to genomic instability, immunodeficiency, and developmental defects, underscoring its importance in maintaining genome integrity.

Anti-XLF antibodies are widely used in molecular biology and clinical research to study NHEJ mechanisms, particularly in contexts like cancer (where DSB repair dysregulation is common) and immune system development (via V(D)J recombination). These antibodies enable detection of XLF expression levels, localization, and interactions through techniques like Western blotting, immunofluorescence, and immunoprecipitation. They also serve as biomarkers in diagnosing XLF-related disorders, such as microcephaly or radiation-sensitive severe combined immunodeficiency (RS-SCID). Commercial Anti-XLF antibodies are typically validated for specificity, often targeting conserved regions of the protein (e.g., human XLF’s C-terminal domain), and are essential for advancing studies on DNA repair pathways and therapeutic targeting of genomic instability diseases.